Comparative Pharmacology
Head-to-head clinical analysis: ARESTIN versus AUREOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTIN versus AUREOMYCIN.
ARESTIN vs AUREOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
None Documented
None Documented
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic